The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe Asthma

People with severe asthma account for 5% to 10% of all asthmatic patients; however, this small group uses the majority of health care resources. Novel methods are needed to cope with the burden that this minority of patients places on the health care system. A severe asthma clinic patient, who was m...

Full description

Saved in:
Bibliographic Details
Main Authors: Anmol S Kapoor, Sharla-Rae Olsen, Cindy O’Hara, Lakshmi Puttagunta, Dilini Vethanayagam
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:Canadian Respiratory Journal
Online Access:http://dx.doi.org/10.1155/2009/206506
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849405132315295744
author Anmol S Kapoor
Sharla-Rae Olsen
Cindy O’Hara
Lakshmi Puttagunta
Dilini Vethanayagam
author_facet Anmol S Kapoor
Sharla-Rae Olsen
Cindy O’Hara
Lakshmi Puttagunta
Dilini Vethanayagam
author_sort Anmol S Kapoor
collection DOAJ
description People with severe asthma account for 5% to 10% of all asthmatic patients; however, this small group uses the majority of health care resources. Novel methods are needed to cope with the burden that this minority of patients places on the health care system. A severe asthma clinic patient, who was monitored through the University of Alberta’s Virtual Asthma Clinic (Edmonton, Alberta) is presented. Despite optimization of his disease and individualized asthma education (provided by a certified asthma educator), the patient remained on oral glucocorticosteroids (OGS) to control his disease. Following optimization and stabilization, a further reduction in the dose of his OGS by the addition of the long-acting anticholinergic agent tiotropium bromide, was demonstrated. The role of tiotropium as a potential ‘steroid-sparing agent’ in severe refractory asthma is discussed, noting that if patients who are on OGS are not monitored for active inflammation, they may overuse the amount of prescribed systemic steroids, which can result in long-term steroid-related sequelae.
format Article
id doaj-art-4715ffc6f7d1486fae4b2bfcaea37299
institution Kabale University
issn 1198-2241
language English
publishDate 2009-01-01
publisher Wiley
record_format Article
series Canadian Respiratory Journal
spelling doaj-art-4715ffc6f7d1486fae4b2bfcaea372992025-08-20T03:36:45ZengWileyCanadian Respiratory Journal1198-22412009-01-011639910110.1155/2009/206506The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe AsthmaAnmol S Kapoor0Sharla-Rae Olsen1Cindy O’Hara2Lakshmi Puttagunta3Dilini Vethanayagam4Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaPulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaPulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaPulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaPulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaPeople with severe asthma account for 5% to 10% of all asthmatic patients; however, this small group uses the majority of health care resources. Novel methods are needed to cope with the burden that this minority of patients places on the health care system. A severe asthma clinic patient, who was monitored through the University of Alberta’s Virtual Asthma Clinic (Edmonton, Alberta) is presented. Despite optimization of his disease and individualized asthma education (provided by a certified asthma educator), the patient remained on oral glucocorticosteroids (OGS) to control his disease. Following optimization and stabilization, a further reduction in the dose of his OGS by the addition of the long-acting anticholinergic agent tiotropium bromide, was demonstrated. The role of tiotropium as a potential ‘steroid-sparing agent’ in severe refractory asthma is discussed, noting that if patients who are on OGS are not monitored for active inflammation, they may overuse the amount of prescribed systemic steroids, which can result in long-term steroid-related sequelae.http://dx.doi.org/10.1155/2009/206506
spellingShingle Anmol S Kapoor
Sharla-Rae Olsen
Cindy O’Hara
Lakshmi Puttagunta
Dilini Vethanayagam
The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe Asthma
Canadian Respiratory Journal
title The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe Asthma
title_full The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe Asthma
title_fullStr The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe Asthma
title_full_unstemmed The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe Asthma
title_short The Efficacy of Tiotropium as a Steroid-Sparing Agent in Severe Asthma
title_sort efficacy of tiotropium as a steroid sparing agent in severe asthma
url http://dx.doi.org/10.1155/2009/206506
work_keys_str_mv AT anmolskapoor theefficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT sharlaraeolsen theefficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT cindyohara theefficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT lakshmiputtagunta theefficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT dilinivethanayagam theefficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT anmolskapoor efficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT sharlaraeolsen efficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT cindyohara efficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT lakshmiputtagunta efficacyoftiotropiumasasteroidsparingagentinsevereasthma
AT dilinivethanayagam efficacyoftiotropiumasasteroidsparingagentinsevereasthma